Tectona grandis leaf extract ameliorates hepatic fibrosis: Modulation of TGF- β /Smad signaling pathway and upregulating MMP3/TIMP1 ratio
| Autor: | Ahmad Ali Shahid, Brice Landry Koloko, Ayesha Malik, Somayya Tariq, Sidra Rehman, Bushra Ijaz |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Liver Cirrhosis
Cirrhosis Cell Survival CCL4 Smad2 Protein Pharmacology Protective Agents 03 medical and health sciences chemistry.chemical_compound Hydroxyproline 0302 clinical medicine Fibrosis Transforming Growth Factor beta Drug Discovery Chlorocebus aethiops medicine Hepatic Stellate Cells Animals Humans Sirius Red Carbon Tetrachloride Vero Cells Transaminases 030304 developmental biology Liver injury 0303 health sciences Lamiaceae Tissue Inhibitor of Metalloproteinase-1 biology Dose-Response Relationship Drug Plant Extracts Hep G2 Cells medicine.disease biology.organism_classification Mice Inbred C57BL Plant Leaves Disease Models Animal chemistry Tectona 030220 oncology & carcinogenesis Matrix Metalloproteinase 3 Collagen Hepatic fibrosis Signal Transduction |
| Zdroj: | Journal of ethnopharmacology. 272 |
| ISSN: | 1872-7573 |
| Popis: | Ethnobotanical relevance Tectona grandis L.f (or syn: Jatus grandis (L.f.) Kuntze Revis), from family Lamiaceae, also known as Teak, is widely recognized in ayurvedic system of medicine and confer curative potential against inflammation, liver disorders, biliousness, diabetes, bronchitis, leprosy and dysentery. Its leaves are rich source of edible food colorant and reported nontoxic for liver and various organs. Aim of study Hepatic injury progression to liver cirrhosis and cancer is a serious health issue across the world. Currently, anti-fibrotic therapeutic options are limited and expensive with no FDA approved direct anti-hepato-fibrotic drug validated in clinic. Thus, the aim of this study was to understand ameliorative effect of Tectona grandis L.f, leaves in early liver fibrosis. Method and results C57BL/6 mice suffering from CCl4 induced liver injury, were orally administered at three different doses (50, 100 & 200 mg/kg) of Tectona grandis L.f, leaf extract, thrice a week, up to 4 and 8 weeks. Anti-fibrotic effect was evaluated through animal body/liver weight measurements, serological tests (AST, ALT, GSH, MDA and LDH assays), tissue hydroxyproline content, and histochemical analysis (H&E, Masson trichrome, Sirius red and αSMA localization). Moreover, transcriptional and post-transcriptional expression of fibrosis associated biomarkers and TGF-β/Smad cascade were analyzed. It was observed that 100 mg/kg dose optimally downregulated TGF-β1/Smad2 with upregulation of Smad7 and regulated αSMA, Col 1, PDGF, TIMP1 and MMP3 expression, post 8 weeks of treatment. In addition, MMP3/TIMP1 ratio was upregulated to 0.7, 2.5 and 1.7 fold at 50 mg/kg, 100 mg/kg & 200 mg/kg treatments respectively, in comparison to untreated liver fibrosis models. The extract contains gallic acid, caffeic acid, sinapinic acid and myricetin when analyzed through high performance liquid chromatography. Conclusion Tectona grandis L.f, leaves have potential to ameliorate liver fibrosis induced by CCl4 in mice via modulation of TGF-β1/Smad pathway and upregulated MMP3/TIMP1 ratio. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect